Prolonged survival in patients with local chronic infection after high-grade glioma treatment: Two case reports.
anaplastic astrocytoma
glioblastoma
high-grade glioma
prolonged survival
wound infection
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
10
2022
accepted:
01
12
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
3
1
2023
Statut:
epublish
Résumé
High-grade gliomas are primary brain tumors with poor prognosis, despite surgical treatment followed by radiotherapy and concomitant chemotherapy. We present two cases of long-term survival in patients treated for high-grade glioma and concomitant prolonged bacterial wound infection. The first patient treated for glioblastoma IDH-wildtype had been without disease progression for 61 months from the first resected recurrence. Despite incomplete chemotherapy-induced myelosuppression in the second patient with anaplastic astrocytoma IDH-mutant, she died without disease relapse after 14 years from the diagnosis due to other comorbidities. We assume that the documented prolonged survival could be related to the bacterial infection.
Identifiants
pubmed: 36591464
doi: 10.3389/fonc.2022.1073036
pmc: PMC9800515
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1073036Informations de copyright
Copyright © 2022 Solár, Mackerle, Hendrych, Pospisil, Lakomy, Valekova, Hermanova and Jancalek.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunotherapy. 2011 Apr;3(4 Suppl):42-4
pubmed: 21524170
J Clin Neurosci. 1999 Jan;6(1):67-8
pubmed: 18639130
J Immunol. 1998 Nov 15;161(10):5179-86
pubmed: 9820488
Neurosurgery. 2011 Oct;69(4):864-8; discussion 868-9
pubmed: 21900810
Brain Tumor Pathol. 1997;14(1):71-4
pubmed: 9384806
Jundishapur J Microbiol. 2016 Mar 05;9(5):e27297
pubmed: 27540448
Ther Adv Med Oncol. 2017 May;9(5):347-368
pubmed: 28529551
Clin Cancer Res. 2013 Jun 15;19(12):3165-75
pubmed: 23613317
Clin Cancer Res. 2010 Feb 1;16(3):800-13
pubmed: 20103663
Cancer Lett. 2008 Jan 18;259(1):16-27
pubmed: 18063294
J Exp Clin Cancer Res. 2017 Jun 22;36(1):83
pubmed: 28641579
Clin Microbiol Rev. 2009 Apr;22(2):240-73, Table of Contents
pubmed: 19366914
Neurosurgery. 2009 May;64(5):828-34; discussion 834-5
pubmed: 19404146
Front Oncol. 2020 Jul 03;10:840
pubmed: 32719739
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Cancer Immunol Res. 2014 Dec;2(12):1199-208
pubmed: 25300859
J Neurooncol. 2017 Jan;131(1):1-9
pubmed: 27743144
Onco Targets Ther. 2015 Sep 15;8:2555-63
pubmed: 26451114
Neurosurgery. 2007 Feb;60(2):372-80; discussion 381
pubmed: 17290189
Front Surg. 2016 Mar 02;3:11
pubmed: 26973839
Front Neurol. 2021 Feb 05;12:615593
pubmed: 33613432
Oncotarget. 2015 Mar 10;6(7):4569-84
pubmed: 25625193
J Neurosurg. 2017 Oct;127(4):807-811
pubmed: 27935360
Infection. 2021 Apr;49(2):267-275
pubmed: 33034890
Neurosurgery. 2001 Mar;48(3):607-14; discussion 614-5
pubmed: 11270552
Cell Biochem Funct. 2019 Jul;37(5):331-339
pubmed: 31045268
Anticancer Drugs. 2003 Jul;14(6):457-66
pubmed: 12853889
J Neurosurg. 2015 Jan;122(1):61-8
pubmed: 25343184
Nat Rev Neurol. 2022 Apr;18(4):221-236
pubmed: 35277681
Neurosurgery. 1999 Mar;44(3):636-42; discussion 642-3
pubmed: 10069601
Cell Physiol Biochem. 2013;31(4-5):614-24
pubmed: 23652608
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Anticancer Res. 1998 Jul-Aug;18(4A):2499-502
pubmed: 9703899
Neuro Oncol. 2012 Aug;14(8):958-78
pubmed: 22573310
J Immunol. 2004 Oct 1;173(7):4352-9
pubmed: 15383564